Assessment of replication and virulence of attenuated pseudorabies virus in swine.

A nonclinical study was conducted to characterize the replication behavior of a modified live gE-deleted pseudorabies virus (PRV MS+1) in swine and potential for reversion to virulence after animal passages. Two to 3 week-old weaned pigs, negative for PRV, were maintained in isolation and challenged by intranasal instillation. For the first passage, 6 pigs were given 1 mL of PRV MS+1 (10(7.3)TCID(50)/mL) and 2 were necropsied at 3, 4 and 5 days post-inoculation (PI). Brain and secondary lymphoid tissues were collected, homogenized and the supernatants individually pooled for virus isolation, and PRV was recovered from each sample. No clinical signs of PRV infection were observed, but each pig had a nasal swab suspect or positive for PRV. For the second passage, 5 pigs were given 1 mL of the homogenate of mixed tissues from 1 animal in the previous passage (PRV at 10(1.9) TCID(50)/mL). At 5 days PI, all pigs were necropsied, and PRV was not recovered from their tissue homogenates or nasal swabs, and no clinical signs were observed. During a second attempt at a second passage, tissue homogenates from all pigs in the first passage (PRV at approximately 10(1.7)TCID50(50)/mL) were pooled and used to inoculate 15 pigs with 2 mL for 3 consecutive days. Ten pigs were monitored for clinical signs and seroconversion through 21 days PI, and 5 pigs were necropsied at 5 days PI. No clinical signs or PRV antibodies were detected in the 10 monitored pigs, and no PRV was recovered from the homogenates or nasal swabs of the 5 necropsied pigs. Thus, no evidence of reversion to virulence was demonstrated in pigs given the attenuated PRV.

Analysis of latency in cattle after inoculation with a temperature sensitive mutant of bovine herpesvirus 1 (RLB106).

Calves were inoculated with the bovine herpes virus 1 (BHV-1) vaccine strain (RLB 106), which is a temperature sensitive mutant. The route of inoculation was intranasal instillation or intramuscular (i.m.) injection (flank or neck). As a control, five calves were given placebo by i.m. injection of the neck. Regardless of the infection route, clinical symptoms did not occur. However, BHV-1 neutralizing antibodies were detected after inoculation demonstrating that sero-conversion occurred. At 60 days post-inoculation, dexamethasone was given by i.m. injection to attempt reactivation of RLB 106. Only those calves inoculated by the intranasal route shed virus leading to an increase in BHV-1 specific antibodies. As expected, viral DNA and the latency related-RNA were detected in trigeminal ganglia (TG) of calves inoculated by the intranasal route. In contrast, viral nucleic acid was not detected in TG of calves inoculated by the i.m. route or in calves inoculated with placebo. In cervical ganglia or sacral dorsal root ganglia, viral nucleic acid was not consistently detected. This study provides evidence that efficient latency and reactivation does not occur following i.m. inoculation. Since serum-neutralizing antibodies were detected in all inoculated calves, i.m. inoculation led to sero-conversion.

Synchronization of estrus after treatment with Luprostiol in beef cows and in beef and dairy heifers.

Four trials were conducted to study synchronous estrous response in beef cows and in beef and dairy heifers to Luprostiol (13, thia-PG-F(2)alpha analog) in comparison with other prostaglandin products. In Trial 1, 60 virgin beef heifers were observed for estrus for 5 d and artificially inseminated. Heifers not observed in estrus within 5 d were randomly assigned to receive 15 mg Luprostiol or 25 mg Lutalyse. In Trial 2, 75 multiparous, lactating beef cows were randomly assigned to receive either 15 mg Luprostiol, 25 mg Lutalyse or 500 mcg Estrumate. All cows received a second injection of the respective treatment 11 d later. In Trial 3, 96 multiparous, lactating beef cows were randomly assigned to receive 15 mg Luprostiol or 25 mg Lutalyse. All cows received a second injection of the respective treatment 11 d later. In Trial 4, virgin dairy heifers were palpated per rectum. Seventy-seven heifers with a palpable corpus luteum (CL) were randomly assigned to receive 15 mg Luprostiol or 500 mcg Estrumate. In all trials animals were artificially inseminated 12 h following observed estrus. Estrous response during the 5-d synchronized period was 44% for Luprostiol and 42% for Lutalyse treated heifers in Trial 1. It was 52, 56 and 60%, respectively, for Luprostiol, Lutalyse and Estrumate treated cows in Trial 2; 23% for Luprostiol and 19% for Lutalyse treated cows in Trial 3; and 68% for Luprostiol and 70% for Estrumate treated heifers in Trial 4. Treatment with Luprostiol results in a similar synchronous estrous response as with the other prostaglandin products used in these studies.

Dosage response evaluation of luprostiol administered to pregnant sows.

Two trials were completed to investigate the effects of luprostiol in swine. The first trial was to evaluate parturition induced by various dosages of luprostiol compared with those of lutalyse or vehicle. Sows were assigned by random allotment to one of the following treatments on Day 112 of gestation: Group A, control (0 mg luprostiol); Group B (1.88 mg luprostiol); Group C (3.75 mg luprostiol); Group D (7.5 mg luprostiol); Group E (15 mg luprostiol); Group F (10 mg lutalyse). All prostaglandin-treated groups farrowed earlier than the controls (P<0.05), with Groups D (26.3 h), E (31.0 h) and F (25.8 h) having the shortest treatment-to-first-pig intervals, and Groups A (76.0 h), B (54.4 h) and C (40.0 h) having the longest intervals. Luprostiol-treated sows had the shortest farrowing time (P<0.05; range = 3.2 to 3.9 h). Significant differences were found for the time (min) between births: Group A (32.1), Group B (28.4), Group F (35.5) took longer than Group C (20.2), Group D (21.0) and Group E (21.6). In a second trial, 20 crossbred pregnant sows received either vehicle or luprostiol (7.5 mg) on Day 112 of gestation. Progesterone concentrations declined rapidly (P<0.05) in luprotiol treated females but were unchanged in control females during the 24-h collection period. The results of these trials show 7.5 mg luprostiol to be the most effective dose for inducing farrowing.

Endocrine, estrous and pregnancy response to varying dosages of Luprostiol in beef cows.

Multiparous lactating beef cows were observed for estrus and randomly assigned to one of four Luprostiol (13, thia-PG-F(2)alpha analog) treatment groups receiving 3.8 (LI), 7.5 (LII), 15 (LIII) or 30 (LIV) mg Luprostiol, respectively, or to an untreated control group (C), or to a positive control group (E) receiving 500 mcg Estrumate. Cows received their respective treatments in a single dosage on Day 7, 8 or 9 of the estrous cycle (estrus = Day 0) and were artificially inseminated 12 h following the subsequent estrus. Blood samples were collected from all groups immediately prior to treatment and at 12-h intervals to 48 h post treatment and analyzed for progesterone (P(4)). Blood samples were collected at 3-h intervals from 24 to 72 h post treatment for animals in Group LIII and for 48 h (or observed estrus) starting on Day 19 of the estrous cycle for animals in Group C. These samples were analyzed for estradiol-17beta(E(2)), follicle stimulating hormone (FSH) and luteinizing hormone (LH). Treatment with Luprostiol at doses >/= 7.5 mg resulted in a synchronous estrous response during the first 5 d post treatment in 75 to 95% of cows treated. Luteal function, as evaluated by systemic P(4) concentration, paralleled results observed for estrous response. Treatment with a 15 or 30 mg dose of Luprostiol resulted in greater overall pregnancy rate at synchronized estrus. No biologically significant differences were found in blood levels of E(2), FSH or LH around the time of estrus between cows in Groups C and LIII. Results from these studies indicate treatment with Luprostiol at doses >/= 7.5 mg resulted in a synchronous estrus during the first 5 d after treatment. Pregnancy rates and endocrine changes were similar to those observed in control and Estrumate-treated cows.

Reproductive characteristics of cyclic beef heifers treated with the prostaglandin analog luprostiol.

One hundred and twenty crossbred Angus heifers, after exhibiting a 17- to 23-d estrous cycle, were placed into six groups of 20 heifers each and administered 2 ml i.m. propylene glycol containing either 0 (controls), 3.75, 7.5, 15.0 or 30.0 mg of luprostiol, or saline containing 0.5 mg cloprostenol (Groups 1 through 6, respectively). Heifers were observed for estrus every 6 h and all treatments were given 6.5 to 8.0 d after heifers were observed in standing estrus. Blood samples were collected after treatments from 10 heifers in each groups. Blood serum was assayed for progesterone. The synchronization period was considered to be 120 h after administration of luprostiol or cloprostenol. There were 0, 16, 17, 18, 20 and 18 heifers observed in estrus during the synchronization period in Groups 1 through 6, respectively. Progesterone concentrations in blood serum dropped below 1 ng/ml in 0, 8, 9, 10, 10 and 10 of the heifers from which blood samples had been taken in the six groups. All heifers observed in estrus were artificially inseminated. During the synchronization period, 0, 12, 14, 15, 16 and 10 heifers conceived in Groups 1 through 6, respectively. The interval from injection to estrus for the 89 heifers that exhibited estrus in the synchronization period averaged 49.0 h and was not different among the luprostiol and cloprostenol treated groups. Control heifers returned to estrus an average of 13.2 d after the treatment. The number of heifers that conceived at first insemination, regardless of when estrus occurred, was 16, 15, 16, 16, 16 and 12, and the total number that conceived at the first and second inseminations was 18, 18, 17, 19, 19 and 16 for Groups 1 through 6, respectively. Based on serum progesterone concentration and/or interval from treatment to estrus, 15 and 30 mg of luprostiol effectively regressed corpora lutea (100%) when administered between 6.5 and 8.0 d after estrus, and the estrous response and conception rate for these two groups equalled or exceeded that of the control and cloprostenol groups.

Efficacy of the morantel sustained-release bolus in grazing cattle in North America.

The efficacy of using a bolus containing morantel in a sustained-release preparation for controlling naturally acquired gastrointestinal parasitic infections in weaned calves and yearling cattle was investigated during the 1982 grazing season at selected sites in the United States and Canada. According to a common trial design under various climatic and management conditions, 10 field trials were conducted with the bolus. At the time of spring turnout, a bolus was administered to each calf or yearling in the treated group. Then, treated and control cattle grazed separate but equal areas of divided pasture(s). The epidemiologic pattern of parasitic gastroenteritis in control animals and the effect of treatment on this pattern was determined in each trial. Safety and practicality of use of the bolus also were established. When compared with untreated cattle (control), those given the bolus deposited significantly (P less than 0.05) fewer worm eggs (89% reduction) during the first 90 days of the grazing season, as well as significantly fewer (P less than 0.05) worm eggs (84% reduction) during the entire grazing season. Consequently, during the second half of the grazing season, larval populations on treated pastures remained significantly (P less than 0.05) lower (66% reduction), compared with numbers of larvae found on control pastures. For pastures grazed by treated and control cattle at trial initiation, mean worm counts recovered from tracer calves were equal, indicating comparable pasture contamination at the beginning of the grazing season.(ABSTRACT TRUNCATED AT 250 WORDS)

Autumn acquisition of nematodes by calves given a morantel sustained-release bolus the preceding spring.

Reinfection with nematodes late in the grazing season was assessed in calves treated the preceding spring with a morantel sustained-release bolus (MSRB). During an initial 155-day grazing period, MSRB-treated calves (n = 15) grazed a pasture used the preceding year for identically treated calves (MSRB pasture). Control calves (n = 15) were not given anthelmintic treatment in the spring and grazed heavily contaminated herbage for the initial 155-day period (control pasture). At the end of the initial grazing period, 3 calves from each group were killed for parasite recovery and counting, with control calves found to harbor 9.2 times more nematodes, compared with the MSRB-treated calves. Nematode counts from tracers killed periodically during the initial grazing period were of similar proportions, reflecting the much greater nematode exposure experienced by the control calves, compared with the MSRB-treated calves. At the end of the initial grazing period, 10 calves (5/group) were placed on a common, contaminated pasture after all were treated twice with fenbendazole (10 mg/kg of body weight, 7 days apart) while on concrete. The second grazing period was for 29 days, followed by a 3-day confinement on concrete. Then, the calves were killed and necropsied. During the 29-day grazing period, the MSRB-treated calves maintained their weight advantage over the control calves, and significant differences in nematode egg counts were not found between the 2 groups of calves. At necropsy, the MSRB-treated calves harbored 27.9% fewer nematodes than did the controls, indicating that prior therapeutic and prophylactic anthelmintic activities of the MSRB did not predispose the animals to enhanced acquisition of nematodes after MSRB protection.

Evaluation of the morantel sustained release bolus in cows and calves.

The efficacy of the morantel sustained release bolus (MSRB) in controlling gastrointestinal parasitism in beef cattle was assessed during the 1982 spring-autumn grazing season. Forty-eight cows and their calves were allotted to three equal groups. One group (T-1) served as a nonmedicated control group. One MSRB was administered to each calf of the T-2 group, and to each cow and calf of the T-3 group at the beginning of the study. The efficacy of the bolus was assessed by comparison of weight gain performance and parasitological data (fecal worm egg counts, herbage larval counts, worm counts from tracer and principal trial calves, and plasma pepsinogen level determinations). Though not statistically significant, treated calves from Group T-2 had a numerical mean weight gain advantage of 2.6 kg, and those from Group T-3 of 4.7 kg, over control calves. Average daily gains (ADG) for the three groups of calves were 0.69, 0.72, and 0.73 kg, respectively. Untreated cows from Group T-2 and treated cows from Group T-3 outperformed the control cows by 12.3 and 7.5 kg, respectively. Fecal worm egg counts from both groups of treated calves were significantly (P less than 0.01) lower than counts from control calves during the entire 169-day trial; notably, egg counts were reduced by 99% 28 days after MSRB administration to both groups of calves. There were no significant differences in the number of eggs counted from the three groups of cows, probably because of the very low numbers of eggs encountered. Mean total worm burdens of principal calves (six per group) necropsied at trial termination indicated a 91% (P less than 0.01) reduction in Group T-2 and an 87% reduction (P less than 0.01) in Group T-3. Worm-free tracer calves were introduced onto pastures every 28 days to monitor availability of infective larvae. The mean number of worms recovered at necropsy from tracer calves that grazed with control cattle increased as the season progressed. However, the numbers of parasites recovered each month from mid-August through mid-October from tracers that grazed pastures with treated cattle were lower (P less than 0.05) than those levels displayed at trial initiation. In addition, the mean numbers of worms from treated group tracers were lower than from the controls for each necropsy period.(ABSTRACT TRUNCATED AT 400 WORDS)

Efficacy of morantel sustained release bolus against gastrointestinal nematodes in first season grazing Holstein calves.

The efficacy of the morantel sustained release bolus (MSRB) in reducing gastrointestinal parasitism in first season grazing calves was evaluated during the summer--autumn grazing seasons of 1982 and 1983 in western Oregon. Each of 38 calves (1982) and 40 calves (1983) were randomly assigned to either control or treatment groups which were given MSRB on the day of turnout onto pasture. Mean worm burdens from tracer calves grazed with treated animals in 1982 and 1983 showed overall reductions of 86.4% (P greater than 0.05) and 84.3% (P less than 0.01), respectively, compared to tracers grazed with controls. Ostertagia ostertagi, Cooperia oncophora and Nematodirus helvetianus were the primary nematodes collected at necropsy. Twelve full-season 1982 tracer animals (6 treated and 6 control) indicated an 88.1% (P less than 0.05) overall reduction in mean worm burdens. Mean fecal worm egg per gram (EPG) counts of treated animals reflected a reduction of 69% (P less than 0.05) in 1982 and 90% (P less than 0.05) in 1983. Autumn inhibition of O. ostertagi was observed. In the 1982 trial the control animals showed a slight mean weight gain advantage over the treated group from Day 84 until Day 160 (trial termination) when the mean difference was 7.9 kg. The final mean weight gain advantage of treated animals in 1983 was 13.5 kg (P less than 0.05). These trials demonstrated that the MSRB was an effective anthelmintic for reducing gastrointestinal parasitism in grazing calves and for decreasing pasture larval contamination.

Release of LH, FSH and GnRH into pituitary venous blood in mares treated with a PGF analogue, luprostiol, during the transition period.

Nine mares received cannulae to collect blood from the pituitary venous outflow in the intercavernous sinus (ICS) and the jugular vein; in 4 mares, only jugular cannulae were used. Those 4 mares and 3 of the mares with cannulae in both positions received 7.5 mg luprostiol i.m. and 1 mare with both cannulae was treated with 3.75 mg uprostiol i.v. Blood samples were kept before and after treatment at 2-, 5- or 10-min intervals and concentrations of LH, FSH and GnRH were determined by RIA. Treatments resulted in an immediate sharp rise of LH and FSH in ICS and jugular blood samples within 2-10 min, with ICS concentrations rising earlier, and with peak levels of LH 8 to 100 times higher, respectively. In ICS samples, GnRH was elevated consistently only after LH and FSH had reached peak levels. At both locations, LH and FSH concentrations remained elevated 60-120 min after treatment, but had returned to baseline by 240 min. In 5 untreated mares with cannulae at both locations, sampling at 5-min intervals for 12 or 24h revealed no pulses of LH or FSH in 3 mares, and only one pulse a day, preceded by several small rises of GnRH during the hour before the pulses, in 2 mares.

Responses of cats to nasal vaccination with a live, modified feline herpesvirus type 1.

Intranasal vaccination with a cold-adapted strain of feline herpesvirus type 1 (FHV-1) two days before challenge gave partial protection, and four days before challenge gave complete protection, against feline viral rhinotracheitis. Protection at this time appeared to be specific since vaccination with FHV-1 did not affect the disease caused by the unrelated feline calicivirus. The time course of onset of protection also confirmed that the protective mechanism was likely to be specific. However, six days after vaccination only low levels of FHV-specific IgA and IgM antibody and of interferon were found in serum and nasal washings. In lymphocyte transformation assays neither peripheral blood lymphocytes nor tonsil lymphocytes gave a significant proliferative response in the presence of FHV antigen. Pathogenesis experiments demonstrated that the tonsil and nasal turbinates were the most important sites of virulent FHV-1 replication. Vaccination significantly reduced levels of infectious virus found in both sites. The results provide evidence that no one mechanism is responsible for protection following vaccination but local specific responses are more likely to be involved.

Efficacy of a morantel sustained-release bolus for the control of gastrointestinal nematodes in Florida dairy heifers.

The effectiveness of a morantel sustained-release bolus (MSRB) in controlling gastrointestinal nematode infections was determined in 70 Holstein heifer calves with no prior grazing experience. Calves were allotted to 2 treatment groups and were maintained in Florida during the grazing season on divided pastures of equal area. One MSRB was administered to each calf in 1 group at the time of turnout onto spring pasture, whereas calves in the other group remained as nonmedicated controls. By the end of the grazing season, treatment resulted in significantly (P less than 0.05) lower worm burdens and significantly improved weight gains. The MSRB-treated calves were able to reach breeding weight 2 to 4 weeks earlier than did nonmedicated calves.

Efficacy of morantel against nematode populations in calves exposed on a pasture stocked for two years with morantel sustained-release bolus-treated calves.

Two groups of 10 parasite-free calves were maintained either for 2 weeks on a pasture grazed by nonmedicated cattle (pasture A) or for 3 weeks on a pasture grazed by morantel sustained-release bolus-treated cattle (pasture B) for the preceding 2 years. After a 4-week holding period to allow for maturation of acquired gastrointestinal nematodes, 5 calves from each group were administered a therapeutic dose (10 mg/kg of body weight) of morantel tartrate. All calves were necropsied 1 week later, and the abomasal and small intestinal nematodes were isolated, identified, and enumerated. A comparison of efficacies between nonmedicated and morantel tartrate-treated calves of each pasture demonstrated that morantel was equally effective against the gastrointestinal nematode infections, regardless of infection source (ie, pasture A vs pasture B). The overall nematode reductions due to morantel tartrate treatment of calves that grazed pastures A and B were 98% and 96%, respectively. It was concluded that the sensitivity of gastrointestinal nematodes to morantel tartrate was not diminished in calves maintained on pasture B, which had been stocked with morantel sustained-release bolus-treated calves for the preceding 2 grazing seasons.

Nonimmune binding of equine immunoglobulin by the causative organism of contagious equine metritis, Taylorella equigenitalis.

This study identifies nonimmune binding of equine immunoglobulin by the causative organism of contagious equine metritis. Immunoglobulin binding to the bacterium was strongest for immunoglobulin G (IgG) and less for IgM; IgA was not bound. Binding of equine IgG was inhibited by human IgG, but not by IgG of domestic animals. Immunoglobulin binding by the bacterium appeared to be directed towards an epitope in the hinge region of the immunoglobulin molecule.

Field efficacy of a morantel sustained release bolus for control of gastrointestinal nematodes in yearling steers.

The efficacy of a morantel sustained release bolus (MSRB) for control of gastrointestinal nematodes in yearling steers was evaluated over a 6-month grazing period commencing on 26 March 1982. Three groups of 15 steers were allotted to the following treatments: Group 1 -- one MSRB at start of trial; Group 2 -- one therapeutic dose of thiabendazole at start of trial; Group 3 -- untreated control. The treatment groups were grazed separately. Parasite egg counts (EPG), herbage larval counts, pepsinogen levels and weight gains were monitored. Every other month, sets of 2 parasite-free tracer calves were placed in the pasture grazed by each treatment group and allowed to graze for 3 weeks before being subsequently necropsied for worm counts. At the end of the trial, 6 animals from each group were also necropsied for worm counts. The MSRB treatment resulted in significantly lower egg counts, fewer infective larvae on pasture, lower pepsinogen levels and lower worm burdens in tracer calves than was the case for the untreated group, but generally the levels were not significantly different from those associated with the thiabendazole treatment. The mean weight gain for the MSRB treated steers showed a significant advantage (70.9 lb) over the untreated animals, but was not significantly different from those which received thiabendazole. Total worm counts at the end of the trial were not different from any treatment group.

Effect of the morantel sustained-release bolus, used during one grazing season, on the sensitivity of Ostertagia and Cooperia to morantel tartrate in calves.

Infective 3rd-stage larvae of Ostertagia and Cooperia, obtained from the feces of nonmedicated and morantel sustained-release bolus (MSRB)-treated calves, were orally administered to 2 groups of parasite-free calves. After a 42-day maturation period, a therapeutic dose of morantel tartrate was administered to half of the calves from each group. All calves were necropsied 7 days after treatment. After comparing the nematode counts for the nonmedicated and morantel-treated calves of each group, morantel tartrate was demonstrated to be equally effective against the nonmedicated-derived and MSRB-derived nematode populations. The sensitivity of Ostertagia spp and Cooperia spp to morantel tartrate, therefore, was not diminished after use of the MSRB for a single grazing season.

The importance of dietary antigen in the cause of postweaning diarrhea in pigs.

Food was given to pigs before weaning to determine whether a hypersensitive response to dietary antigen might be a predisposing factor to postweaning diarrhea. Small amounts of food increased the severity and accelerated the onset of postweaning diarrhea. Postweaning diarrhea was dependent on the presence within the diet of antigenic material (bovine casein). A weaning diet, containing little antigenic material (hydrolyzed casein), had less effect on sucrase concentration in intestinal brush borders than did diets rich in antigens (native casein). Seemingly, immune-mediated intestinal damage may predispose the pig to postweaning diarrhea.